Angiomax in Patients with HIT/HITTS Type II Undergoing CPB
This study is currently recruiting patients.
Sponsored by: |
The Medicines Company |
Information provided by: |
The Medicines Company |
Purpose
The purpose of this study is to demonstrate that in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia
and thrombosis syndrome (HITTS) Type II undergoing cardiac surgery on cardiopulmonary bypass (CPB), Angiomax is a safe and
effective anticoagulant.
Condition
|
Treatment or Intervention |
Phase |
Cardiovascular Disease Coronary Artery Bypass Surgery
|
Drug: Angiomax (bivalirudin)
|
Phase III
|
MedlinePlus related topics: Circulatory Disorders; Heart Diseases
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study
Official Title: A Phase III Study of Angiomax (bivalirudin) in Patients with HIT/HITTS Type II Undergoing Cardiac Surgery on Cardiopulmonary
Bypass (CPB)
Further Study Details:
Expected Total Enrollment:
50
Study start: April 2004
An open-label, prospective, multicenter, single-arm study; with a historical reference cohort of similarly identified HIT/HITTS
patients from participating institutions that underwent cardiac surgery on CPB with alternative anticoagulation regimens during
the period of approximately 12 months prior to initiation of the first patient into this study.
Eligibility
Ages Eligible for Study:
18 Years and above,
Genders Eligible for Study:
Both
Inclusion Criteria
- Provide written informed consent before initiation of any study-related procedures, and
- Be at least 18 years of age, and
- Be scheduled for CABG, CABG single valve surgery, or isolated single valve surgery on CPB. Patients undergoing repeat (redo)
CABG are also considered eligible for this study, and demonstrated
- New diagnosis or history of objectively documented HIT/HITTS Type II, defined as one or more of the following: a) Positive
heparin-induced platelet aggregation (HIPA) or other functional assay for HIT or immunoassay for HIT antibodies (ELISA), AND/OR
b) HIT: Thrombocytopenia associated with heparin therapy, where the platelet count has decreased by 50%*, OR c) HITTS: Thrombocytopenia
(as defined in B above) PLUS any evidence of arterial or venous thrombosis
Exclusion Criteria
- Confirmed pregnancy at time of enrollment via IVRS (if woman of child-bearing potential) (Urine or serum pregnancy test)
- Cerebrovascular accident within 6 months, or any cerebrovascular accident with a residual neurological deficit.
- Intracranial neoplasm, arteriovenous malformation or aneurysm.
- Dependency on renal dialysis or creatinine clearance <30mL/min.
- Ongoing treatment with warfarin (or other oral anticoagulant) at the time of enrollment. Patients previously treated with
warfarin may be enrolled if warfarin therapy can be safely discontinued and baseline INR is < 1.3 times control in the absence
of heparin therapy.
- Known allergy to Angiomax or hirudin derived drugs, or known sensitivity to any component of the product.
- Patients receiving clopidogrel (Plavix®) within the previous 5 days may be enrolled if in the opinion of the Investigator
the benefits of surgery outweigh the risk associated with recent clopidogrel administration.
- Patients receiving a glycoprotein IIb/IIIa inhibitor within the previous 48 hours prior to enrollment if abciximab (ReoPro®)
or 12 hours if eptifibatide (Integrilin®) or tirofiban (Aggrastat®), may be enrolled if in the opinion of the Investigator
the benefits of surgery outweigh the risk associated with not waiting the 48 or 12 hour time period prior to enrollment.
- Patients receiving lepirudin (Refludan®) or argatroban within the previous 24 hours prior to enrollment. Patients currently
receiving lepirudin or argatroban can be enrolled if they are switched to Angiomax at least 24 hours prior to the planned
cardiac surgery.
- Patients receiving LMWH or thrombolytics within the previous 12 hours may be enrolled if in the opinion of the Investigator
the benefits of surgery outweigh the risk associated with not waiting the 12 hour time period.
- Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within
30 days of enrollment.
- Refusal to undergo blood transfusion should it become necessary.
- Any other disease or condition, which, in the judgment of the Investigator, would place a patient at undue risk by being enrolled
in the trial, or cause inability to comply with the trial.
- Planned surgical procedure in which proximal anastomoses will precede distal anastomoses of the bypass grafts.
- Planned (>1) double (or greater) valve repair-replacement (e.g.: AVR-MVR) surgery.
Location
and Contact
Information
Ohio The Cleveland Clinic, Cleveland,
Ohio,
44195,
United States; Recruiting
Nicholas Smedira, MD
216-444-2200
A. Michael Lincoff, MD
216-444-2200
Nicholas Smedira, MD, Principal Investigator
A. Michael Lincoff, MD, Principal Investigator
Study chairs or principal investigators
Malcolm Lloyd, MD, Study Director, The Medicines Company
More Information
Study ID Numbers:
TMC-BIV-02-03; CHOOSE-On
Record last reviewed:
October 2004
Record first received:
March 9, 2004
ClinicalTrials.gov Identifier:
NCT00079508Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-11-10